realistic expectations, page-30

I made the point that this whole sage was destined to fail, because the traditional model for Biotech (ie get cash flow from the first product to fund 2nd etc), was being dumped, for what effectively was a pie in the sky idea that investors would see this new model as better.

Given the choice of investing in ACL as a Biotech WITH cashflow including a promising Oncology program, or investing in the spin off and therefore riskier Oncology ONLY asset - which one would you choose?
Its no a brainer - surely you take the one with establish cash flows.

I'm not sure whether to blame the idiotic insto's who thought up the idea or the naive management who got sold pup.
Either way if reports that this saga cost $5mill are true, its a huge waste of dwindling resources, and more important dramatically erodes the credibility of the managment, and any future plans they proffer.
For the sake of the future SP it maybe time for heads to role, and a new broom to sweep clean.